CYP-associated drug–drug interactions : a mission accomplished?

Pelkonen, Olavi; Hakkola, Jukka; Hukkanen, Janne; Turpeinen, Miia (2020-10-06)
 
Avaa tiedosto
Lataukset: 

URL:
https://doi.org/10.1007/s00204-020-02912-1

Pelkonen, Olavi
Hakkola, Jukka
Hukkanen, Janne
Turpeinen, Miia
Springer Nature
06.10.2020

Pelkonen, O., Hakkola, J., Hukkanen, J. et al. CYP-associated drug–drug interactions: A mission accomplished?. Arch Toxicol 94, 3931–3934 (2020). https://doi.org/10.1007/s00204-020-02912-1

https://rightsstatements.org/vocab/InC/1.0/
© Springer-Verlag GmbH Germany, part of Springer Nature 2020. This is a post-peer-review, pre-copyedit version of an article published in Arch Toxicol. The final authenticated version is available online at https://doi.org/10.1007/s00204-020-02912-1.
https://rightsstatements.org/vocab/InC/1.0/
doi:https://doi.org/10.1007/s00204-020-02912-1
Näytä kaikki kuvailutiedot
Julkaisun pysyvä osoite on
https://urn.fi/URN:NBN:fi-fe2020113098699
Tiivistelmä

Abstract

On the basis of official Finnish Medicines Authority (Fimea)-approved drug monographs, less than half of the approved small-molecule drugs between 2007 and 2016 were substrates, inhibitors or inducers of CYP enzymes, predominantly of CYP3A4. No significant unexpected, life-threatening, CYP-associated drug-drug interactions (CYP-DDIs) of newly approved drug entities have been observed in the last 10–15 years. The present analysis seems to suggest that tools to study and predict potentially significant CYP-DDIs are working and efficient.

Kokoelmat